MedPath

Pharmacogenetic and Antidepressant Treatment in Elderly

Not Applicable
Terminated
Conditions
Depression
Registration Number
NCT02856477
Lead Sponsor
Centre Hospitalier Universitaire de Besancon
Brief Summary

The study aims to assess the therapeutic benefits of the adaptation of the antidepressant dose to the metabolic capacity (cytochrome P450 2D6) of elderly depressed patients.

Therapeutic benefits are evaluated through the enhancement of efficiency, decrease of the action time and the after effects.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
28
Inclusion Criteria
  • current major depressive disorder
  • antidepressant treatment
Exclusion Criteria
  • dextromethorphan contra-indication
  • other psychiatric disorder
  • kidney failure
  • liver failure mini mental State Examination (MMSE)<18

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
patient remission6 months

remission is defined by a Montgomery and asberg depression rating (MADRS) score\<10.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHU Besancon

🇫🇷

Besancon, Doubs, France

CHU Besancon
🇫🇷Besancon, Doubs, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.